Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.60 |
| ▸ | ASIC3 | Q9UHC3 | 5/20 | 0.49 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | CD44 | P16070 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22866959 | 0.78 | CD274 (0.86) | CD274ASIC3PNMTCD44MAOB | |
| SCHEMBL4553211 | 0.78 | CD274 (0.60) | CD274ASIC3SYKPNMTCD44 | |
| SCHEMBL25405965 | 0.77 | CD274 (0.74) | CD274ASIC3SYKPNMTCD44 | |
| SCHEMBL20294456 | 0.77 | CD274 (0.80) | CD274ASIC3PNMTCD44MAOB | |
| SCHEMBL1906811 | 0.77 | TRPA1 (0.48) | TRPA1 | |
| SCHEMBL3704728 | 0.76 | CD274 (0.55) | CD274ASIC3SYKPNMTCD44 | |
| SCHEMBL18554761 | 0.75 | CYP3A4 (0.52) | CD274ASIC3PNMTCD44MAOB | |
| SCHEMBL25402840 | 0.75 | CD274 (0.61) | CD274ASIC3PNMTCD44MAOB | |
| SCHEMBL3703063 | 0.75 | CD274 (0.54) | CD274ASIC3SYKPNMTCD44 | |
| SCHEMBL22807512 | 0.75 | CD274 (1.00) | CD274ASIC3PNMTCD44MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731954-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RES INC (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731954-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, BMI1 | CD274 2901/4885ASIC3 4250/4885SYK 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.